Zacks Investment Research on MSN
Biogen wins FDA approval for subcutaneous starter dose of Leqembi
Shares of Biogen BIIB rose nearly 5% yesterday after the company announced that the FDA approved a subcutaneous (SC) ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results